Últimas noticias sobre Natera (NASDAQ:NTRA) Bolsa

NATERA INC

Natera

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Equities

News

Markets

Tech

General

ADBE

ADSK

AMZN

AVGO

GOOGL

MSFT

NTRA

NVDA

SBUX

TEVA

TSLA

Stanley Druckenmiller vendió todas sus acciones en Broadcom tras su alza del 100% y reforzó su inversión en grandes tecnológicas.

El nuevo giro de Druckenmiller: vende Broadcom y amplía su apuesta en tecnológicas clave

Natera Inc

RBC Capital analyst Conor McNamara initiates coverage on Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Outperform rating and announces Price Target of $251.

Price Target

Initiation

Analyst Ratings

RBC Capital Initiates Coverage On Natera with Outperform Rating, Announces Price Target of $251

Natera's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NYSE">NTRA</a>) short percent of float has fallen 44.35% since its last report. The company recently reported that it has 2.49 million shares sold short, which is 1.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Natera Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741723238_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Natera has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Natera's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Natera's peer group average for short interest as a percentage of float is 5.68%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Do Investors Really Feel About Natera?

Morgan Stanley analyst Tejas Savant maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $176 to $185.

Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $185

Piper Sandler analyst David Westenberg maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $200 to $205.

Piper Sandler Maintains Overweight on Natera, Raises Price Target to $205

Health Care

Natera Receives New Patent Related To Testing Of Single Nucleotide Variants In Circulating-Tumor DNA

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $192.56, a high estimate of $200.00, and a low estimate of $180.00. This current average reflects an increase of 13.44% from the previous average price target of $169.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1740772825_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Natera is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$188.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Julia Qin</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Natera. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Natera compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Natera's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Natera's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NTRA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Natera analyst ratings.</a>
<h2>Delving into Natera's Background</h2>
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
<h3>Natera: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Natera showcased positive performance, achieving a revenue growth rate of 63.9% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Natera's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -7.18%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Natera's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.68%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Natera's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.03%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Natera's debt-to-equity ratio is below the industry average at 0.54, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Natera Stock: Analyst Perspectives (9 Ratings)

Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Buy and raises the price target from $180 to $195.

Canaccord Genuity Maintains Buy on Natera, Raises Price Target to $195

Baird analyst Catherine Ramsey maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Outperform and raises the price target from $183 to $188.

Baird Maintains Outperform on Natera, Raises Price Target to $188

025 gross margin to be approximately 60% to 64% of revenues; selling, general and administrative costs to be approximately $950 million to $975 million; research and development costs to be $525 million to $550 million; and net cash inflow to be positive.

Guidance

Natera Anticipates 2025 Total Revenue Of $1.87B - $1.95B, Est $1.819B

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.42) by 2.38 percent. This is a 36.92 percent increase over losses of $(0.65) per share from the same period last year. The company reported quarterly sales of $476.10 million which beat the analyst consensus estimate of $428.55 million by 11.10 percent. This is a 53.04 percent increase over sales of $311.10 million the same period last year.

Earnings

Earnings Beats

Natera Q4 2024 GAAP EPS $(0.41) Beats $(0.42) Estimate, Sales $476.10M Beat $428.55M Estimate

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Buy and maintains $180 price target.

Canaccord Genuity Maintains Buy on Natera, Maintains $180 Price Target

Natera Meets Coverage Requirements For Signatera For Surveillance In Lung Cancer

Billionaire investor Stanley Druckenmiller&#8216;s family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent 13-F filing.
What Happened: According to a recent&nbsp;SEC filing, Druckenmiller, a seasoned investor, sold all his shares of&nbsp;Broadcom Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) in the fourth quarter. This move comes on the heels of his total exit from Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), a competing chipmaker, a few months prior.
In the closing months of 2024, Druckenmiller significantly reduced his tech stock portfolio, selling his entire stakes in&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>),&nbsp;Adobe Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) and&nbsp;Autodesk Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>). He also completely sold his stake in&nbsp;Starbucks Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) and his shares in insurance company&nbsp;Chubb Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>).
Despite these divestments, Druckenmiller increased his investments in several big tech companies in the same quarter, acquiring new positions in&nbsp;Alphabet Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>),&nbsp;Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Elon Musk&#8216;s electric vehicle manufacturer&nbsp;Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
Druckenmiller&#8217;s Duquesne also initiated new investments in United Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NYSE">UAL</a>), Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), Warner Bros. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NYSE">WBD</a>), Skechers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>), and Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
The most significant holding in his Duquesne Family Office remains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), the clinical genetic-testing company in which they held a stake since 2022. Natera holdings account for just over 15% of the portfolio. Meanwhile, the firm increased its stake in Teva Pharmaceuticals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) by nearly 6.3 times. 
SEE ALSO: <a href="https://www.benzinga.com/25/02/43649046/warner-bros-jinjiang-international-collaborate-for-harry-potter-studio-tour-in-shanghai">Warner Bros Announces Shanghai Harry Potter Studio Tour—Set To Be Four Times Larger Than London&#8217;s</a>
Why It Matters: Druckenmiller, who formerly managed hedge funds for George Soros, now manages his own wealth through the Duquesne Family Office, which has investments worth nearly $3.72 billion.
The billionaire investor&#8217;s latest moves follow his earlier divestments in AI stocks. During the third quarter of 2024, <a href="https://www.benzinga.com/markets/equities/24/12/42668157/stanley-druckenmiller-dumps-streets-hottest-ai-stocks-heres-what-the-billionaire-investor-is-betting-on-next">Druckenmiller sold all of its Nvidia shares and significantly reduced its Palantir holdings</a> by 95%. This occurred despite Nvidia and Palantir experiencing significant stock surges that year, with Nvidia&#8217;s stock increasing nearly 190% and Palantir&#8217;s shares gaining over 386%. 
The current quarter&#8217;s exit from Broadcom despite the stock surging more than 100% over the past year appears as a profit booking move. Meanwhile, other additions in big tech stocks show his growing confidence in the sector.
Druckenmiller added Tesla to its portfolio which surged over 83% in the past year. However, the stock plunged more than 16% over the last month, amid declining global sales, regulatory roadblocks in China, earnings disappointment, and Musk&#8217;s increasing political involvement. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/02/43772576/tesla-to-start-delivering-shanghai-made-refreshed-model-ys-next-week">Tesla&#8217;s Refreshed Model Y Rolls Off Shanghai Gigafactory, Deliveries To Start &#8216;Soon&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has outperformed the market over the past 5 years by 23.29% on an annualized basis producing an average annual return of 36.12%. Currently, Natera has a market capitalization of $23.24 billion. 
Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $457.37 today based on a price of $176.00 for NTRA at the time of writing.
<h3>Natera's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739833208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

CDNA

VRTX

Live On CNBC, Amy Raskin Announces Trimmed Vertex Pharmaceuticals ; Trimmed Kadant Position; Trimmed Natera Position; Bought CareDx

In its updated guidelines for colon cancer1 and for rectal cancer2, NCCN now includes ctDNA as a high risk factor for recurrence in the adjuvant setting, recognizing its prognostic value. This represents a significant step forward as it's the first time the committee has formally recognized ctDNA as being prognostic. The guidelines remain cautious about ctDNA for surveillance, as expected. The NCCN finalized these updates before data from the phase III CALGB (Alliance) / SWOG 80702 study were presented at ASCO GI in January, supporting the predictive nature of Signatera in the adjuvant setting.

Natera Commented On Recent Updates By The NCCN On Circulating Tumor DNA Molecular Residual Disease Testing In The Clinical Practice Guidelines In Oncology For Colon Cancer, Rectal Cancer, And Merkel Cell Carcinoma

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has outperformed the market over the past 5 years by 25.51% on an annualized basis producing an average annual return of 38.05%. Currently, Natera has a market capitalization of $23.14 billion. 
Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $495.06 today based on a price of $175.25 for NTRA at the time of writing.
<h3>Natera's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738854910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today

WIIM

Natera shares are trading higher after the company announced it gained national commercial coverage for fetal RhD NIPT and is expanding its access to noninvasive prenatal testing.

Coverage from one of the largest payors in the country expands access to fetal RhD testing for pregnant patients nationwide

Natera Gains National Commercial Coverage For Fetal RhD NIPT, Expanding Access To Noninvasive Prenatal Testing

Press Releases

Natera to Present New Data at the 2025 ASCO GI Symposium

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

Natera Announces National Commercial Coverage for its Fetal RhD NIPT

NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma

Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025

Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer

Natera Reports Fourth Quarter and Full Year 2024 Financial Results

Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD

Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

Comments

Natera

Noticias

Últimas noticias sobre Natera (NASDAQ:NTRA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL